Ferguson Wellman Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN

Ferguson Wellman Capital Management Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 307,566 shares of the medical research company’s stock after buying an additional 7,988 shares during the period. Amgen comprises about 1.4% of Ferguson Wellman Capital Management Inc.’s holdings, making the stock its 21st largest position. Ferguson Wellman Capital Management Inc.’s holdings in Amgen were worth $86,795,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. OLD National Bancorp IN lifted its position in Amgen by 296.2% during the 2nd quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock worth $5,027,000 after acquiring an additional 13,460 shares in the last quarter. Atlantic Union Bankshares Corp raised its stake in shares of Amgen by 165.0% during the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after purchasing an additional 6,627 shares during the period. D.A. Davidson & CO. lifted its position in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after purchasing an additional 6,222 shares in the last quarter. Davis Capital Management purchased a new position in shares of Amgen in the third quarter valued at $1,841,000. Finally, L2 Asset Management LLC grew its holdings in Amgen by 50.8% during the 2nd quarter. L2 Asset Management LLC now owns 9,837 shares of the medical research company’s stock valued at $2,747,000 after purchasing an additional 3,314 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $330.11 on Friday. Amgen Inc. has a twelve month low of $260.55 and a twelve month high of $346.38. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The company has a market capitalization of $177.76 billion, a price-to-earnings ratio of 25.51, a price-to-earnings-growth ratio of 3.11 and a beta of 0.45. The business has a 50 day simple moving average of $329.19 and a 200-day simple moving average of $303.93.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period last year, the business posted $5.58 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent analyst reports. Bank of America boosted their price objective on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Morgan Stanley cut their price target on Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Piper Sandler raised their price objective on Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. BMO Capital Markets upped their target price on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Scotiabank initiated coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $338.55.

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 in the last quarter. Insiders own 0.76% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Acquisition of Dark Blue Therapeutics (up to $840M) adds a preclinical AML degrader and strengthens Amgen’s oncology discovery pipeline, a clear long-term revenue/profitability positive if assets advance. Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
• Positive Sentiment: Exclusive Disco Oncology deal valued at about $618M gives Amgen rights to a cancer target, expanding its oncology footprint and signalizing management’s commitment to M&A/licensing as a growth lever. Amgen dances with Disco in $618M cancer target pact
• Positive Sentiment: Completed Phase 1b blinatumomab study in Japan advances Amgen’s leukemia strategy and supports potential label/market expansion in hematologic cancers. Clinical readouts reduce development risk and could drive upside on future data. Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
• Positive Sentiment: Initiation of a new injection trial for an early-stage obesity candidate signals pipeline diversification beyond oncology and could support medium-term growth as older patents lapse. Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
• Neutral Sentiment: Amgen will present at the 2026 J.P. Morgan Healthcare Conference — an opportunity for management to update guidance and pipeline priorities; results depend on new news or clarity provided. AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
• Neutral Sentiment: Market commentary pieces previewing Q4 2025 results and dividend-stock lists mention Amgen’s efforts to offset a patent cliff with new products; these set expectations but don’t change fundamentals until earnings/data arrive. What to Expect From Amgen’s Q4 2025 Earnings Report
• Negative Sentiment: Coverage noting today’s share decline and market context highlights near-term selling pressure; headlines emphasize the stock fell despite a broader market uptick, which can accelerate outflows. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
• Negative Sentiment: Truist raised its price target slightly to $319 but kept a “hold” rating; the target implies limited near-term upside relative to current levels, which can pressure momentum investors. Benzinga

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.